Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies

NCT01300026 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01300026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01300026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2011
Completion date
December 31, 2016
Enrollment
28 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, chronic lymphocytic leukemia, diffuse large cell lymphoma, hematologic malignancies, hematology, leukemia, low grade lymphoma, lymphoma, mantle cell lymphoma, non-hodgkin's lymphoma, oncology, oncology patients, t cell lymphoma, tumors